Molecular Characterisation of Ovarian Cancer

Grant number: 628779 | Funding period: 2010 - 2012

Completed

Abstract

Ovarian cancer is the 5th most common cancer in women, and most lethal gynaecologic malignancy. Despite aggressive surgery and multi-drug chemotherapy the majority of women experience recurrence and ~70% will succumb to the disease. This project will investigate two molecular subtypes of ovarian cancer previously identified by our laboratory to better understand mechanisms associated with poor treatment response.

Related publications (4)

Scholarly works icon

Acquired chemotherapy resistance in ovarian cancer

EL Christie, DDL Bowtell

2017-11-01

Most women diagnosed with high-grade serous ovarian cancer (HGSC) develop recurrent disease and chemotherapy resistance, despite i..

Scholarly works icon

Selective targeting of Cyclin E1-amplified high-grade serous ovarian cancer by Cyclin-dependent kinase 2 and AKT inhibition

G Au-Yeung, F Lang, WJ Azar, C Mitchell, KE Jarman, K Lackovic, D Aziz, C Cullinane, RB Pearson, L Mileshkin, D Rischin, AM Karst, R Drapkin, D Etemadmoghadam, DDL Bowtell

2017-04-01

Purpose: Cyclin E1 (CCNE1) amplification is associated with primary treatment resistance and poor outcome in high-grade serous ova..

Scholarly works icon

Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes

DJ McBride, D Etemadmoghadam, SL Cooke, K Alsop, J George, A Butler, J Cho, D Galappaththige, C Greenman, KD Howarth, KW Lau, CK Ng, K Raine, J Teague, DC Wedge, AO Cancer Study Group, X Caubit, MR Stratton, JD Brenton, PJ Campbell

2012-08-01

The application of paired-end next generation sequencing approaches has made it possible to systematically characterize rearrangem..

Scholarly works icon

Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer

D Etemadmoghadam, J George, PA Cowin, C Cullinane, M Kansara, KL Gorringe, GK Smyth, DDL Bowtell

2010-12-09

Genomic amplification of 19q12 occurs in several cancer types including ovarian cancer where it is associated with primary treatme..

University of Melbourne Researchers